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The TP53 gene is the most commonly mutated gene in human cancers and mutations
in TP53 have been shown to have either gain-of-function or loss-of-function effects.
Using the data generated by The Cancer Genome Atlas, we sought to define the
spectrum of TP53 mutations in hepatocellular carcinomas (HCCs) and their association
with clinicopathologic features, and to determine the oncogenic and mutational
signatures in TP53-mutant HCCs. Compared to other cancer types, HCCs harbored
distinctive mutation hotspots at V157 and R249, whereas common mutation hotspots
in other cancer types, R175 and R273, were extremely rare in HCCs. In terms of
clinicopathologic features, in addition to the associations with chronic viral infection and
high Edmondson grade, we found that TP53 somatic mutations were less frequent
in HCCs with cholestasis or tumor infiltrating lymphocytes, but were more frequent
in HCCs displaying necrotic areas. An analysis of the oncogenic signatures based
on the genetic alterations found in genes recurrently altered in HCCs identified four
distinct TP53-mutant subsets, three of which were defined by CTNNB1 mutations,
1q amplifications or 8q24 amplifications, respectively, that co-occurred with TP53
mutations. We also found that mutational signature 12, a liver cancer-specific signature
characterized by T>C substitutions, was prevalent in HCCs with wild-type TP53 or
with missense TP53 mutations, but not in HCCs with deleterious TP53 mutations.
Finally, whereas patients with HCCs harboring deleterious TP53 mutations had worse
overall and disease-free survival than patients with TP53-wild-type HCCs, patients
with HCCs harboring missense TP53 mutations did not have worse prognosis. In
conclusion, our results highlight the importance to consider the genetic heterogeneity
among TP53-mutant HCCs in studies of biomarkers and molecular characterization of
HCCs.
Keywords: TP53 mutations, somatic mutations, copy number alterations, mutational signature, oncogenic
signature
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INTRODUCTION
Hepatocellular carcinomas (HCCs) display extensive histologic,
transcriptomic and genetic diversity (Lee et al., 2004;
Boyault et al., 2007; Chiang et al., 2008; Hoshida et al., 2009;
Fujimoto et al., 2012; Guichard et al., 2012; Ahn et al., 2014;
Schulze et al., 2015; The Cancer Genome Atlas Research
Network, 2017). On the genetic level, genes involved in liver
metabolism, Wnt and p53 signaling have been shown to be
recurrently altered (Fujimoto et al., 2012; Guichard et al., 2012;
Ahn et al., 2014; Schulze et al., 2015; The Cancer Genome Atlas
Research Network, 2017). The most frequently mutated protein-
coding genes are CTNNB1 (encoding β-catenin) and TP53
(encoding p53), both mutated in 20–40% of HCCs (Fujimoto
et al., 2012; Guichard et al., 2012; Ahn et al., 2014; Schulze
et al., 2015; The Cancer Genome Atlas Research Network,
2017).
TP53 is the most frequently mutated gene in human cancers
(Kandoth et al., 2013). The p53 protein modulates multiple
cellular functions, including transcription, DNA synthesis and
repair, cell cycle arrest, senescence and apoptosis (Vogelstein
et al., 2000). Mutations in TP53 can abrogate these functions,
leading to genetic instability and progression to cancer
(Vogelstein et al., 2000). Across 12 major cancer types (excluding
HCC), 42% of cancers harbored TP53 somatic mutations,
with at least 20% mutational rate in 10/12 cancer types and
TP53 mutations are associated with inferior prognosis and
unfavorable clinicopathologic parameters, such as tumor stage
(Kandoth et al., 2013). Furthermore, TP53-mutant tumors
are highly enriched among tumors driven by copy number
alterations (CNAs), with most remaining TP53-mutant tumors
associated with the presence of somatic mutations in the Wnt
and/or the RAS-RAF-ERK signaling pathways (Ciriello et al.,
2013).
The pattern of TP53 mutations is reminiscent of both an
oncogene and a tumor suppressor gene (Vogelstein et al.,
2013). The majority (86%) of TP53 mutations are in the DNA-
binding domain (Olivier et al., 2010; Kandoth et al., 2013).
Most mutations in the DNA-binding domain are missense (88%)
and approximately 1/3 of missense mutations affect the hotspot
residues R175, G245, R248, R249, R273, and R282 (Olivier
et al., 2010). Outside the DNA-binding domain, most mutations
(∼60%) are nonsense or frameshift (Olivier et al., 2010). Mutant
p53 proteins may lose the tumor suppressive functions and exert
dominant-negative activities, but may also gain new oncogenic
properties (Olivier et al., 2010; Muller and Vousden, 2014).
Indeed, on the immunohistochemical level, p53 is generally
detectable to various extents in samples with missense mutations
but is undetectable in samples with truncating or frameshift
mutations (Hall and McCluggage, 2006; Soussi et al., 2014).
In HCC, TP53 mutational frequency has been reported to
range between 22 and 33% (Fujimoto et al., 2012; Guichard et al.,
2012; Cleary et al., 2013; Kan et al., 2013; Ahn et al., 2014;
Jhunjhunwala et al., 2014; Shiraishi et al., 2014; Totoki et al., 2014;
Weinhold et al., 2014; Schulze et al., 2015; Fujimoto et al., 2016;
The Cancer Genome Atlas Research Network, 2017). However,
the frequency varies between geographic regions, etiological
factors and carcinogen exposure, with more frequent TP53
mutations in regions where hepatitis B virus (HBV) infection
is endemic (Fujimoto et al., 2012; Guichard et al., 2012; The
Cancer Genome Atlas Research Network, 2017). Similar to other
cancer types, TP53-mutant HCCs have been associated with
features linked to poor prognosis, including high levels of alpha-
fetoprotein, high Edmondson grade, expression of stem-like
markers, and activation of pro-oncogenic signaling pathways
(Kiani et al., 2002; Breuhahn et al., 2004; Lee et al., 2004; Peng
et al., 2004; Boyault et al., 2007; Chiang et al., 2008; Hoshida et al.,
2009; Goossens et al., 2015). Furthermore, patients with TP53-
mutant HCCs tend to have shorter overall (OS) and disease-free
survival (DFS) (Yano et al., 2007; Woo et al., 2011; Cleary et al.,
2013). However, it appears that not all TP53 mutations in HCCs
are equal. For instance, one of the most common mutation
hotspots affecting residues R248/249 has an overall frequency
of ∼10% among TP53-mutant HCCs (Fujimoto et al., 2012,
2016; Ahn et al., 2014; Schulze et al., 2015; The Cancer Genome
Atlas Research Network, 2017). In particular, the R249S mutation
resulting from G>T transversion has specifically been linked to
the combined effect of aflatoxin B1 exposure and HBV infection
(Bressac et al., 1991; Hsu et al., 1991) and this mutation is detected
in >75% of HCC from areas with high aflatoxin B1 exposure
(Gouas et al., 2009; Kew, 2010). Further hotspot mutations
affecting preferentially HCC are located at the residues V157 and
H193 (both at∼2%) (Fujimoto et al., 2012, 2016; Ahn et al., 2014;
Schulze et al., 2015; The Cancer Genome Atlas Research Network,
2017). Both R249S and V157F have been associated with stem
cell-like traits and poor prognosis in HCC patients (Villanueva
and Hoshida, 2011; Woo et al., 2011).
Finally, molecular classification studies have invariably
grouped TP53-mutant HCCs under the umbrella of the
aggressive subclass, but it is also clear that this subclass is
molecularly, biologically and clinically heterogeneous (Boyault
et al., 2007; Hoshida et al., 2009; Goossens et al., 2015).
Given the diverse pattern of TP53 mutations, taking advantage
of The Cancer Genome Atlas (TCGA) dataset, in this study
we sought to determine the pattern of TP53 somatic mutations
in HCCs and its association with clinicopathologic features.
Additionally, as TP53 mutations are associated with HCC
molecular subclasses with poor prognosis, we sought to define
the oncogenic and mutational signatures among TP53-mutant
HCCs.
MATERIALS AND METHODS
Sample Selection and Histologic
Assessment
From TCGA liver hepatocellular carcinoma (LIHC) project (The
Cancer Genome Atlas Research Network, 2017), 373 tumors with
available somatic mutational data1 (accessed April 2017) (Gao
et al., 2013) were included in the study. Images of diagnostic
hematoxylin & eosin (H&E) slides were retrieved from the
cbioportal and reviewed by three expert hepatopathologists (SA,
1http://www.cbioportal.org
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MSM and LMT) according to the guidelines by the World
Health Organization (Bosman et al., 2010) to define the presence
or absence of cholestasis, Mallory bodies, tumor infiltrating
lymphocytes (TILs), vessel infiltration and necrotic areas. 4-point
scale Edmondson and Steiner system was adopted for tumor
grading as previously described (Edmondson and Steiner, 1954;
Alexandrov et al., 2013). Clinical information were obtained from
the cbioportal (Gao et al., 2013).
Classification of TP53 Somatic Mutations
TP53 somatic non-synonymous and splice region mutations for
the 373 HCCs were retrieved from the cbioportal (accessed
April 2017) (Gao et al., 2013). TP53 mutations were stratified
according to (i) the mutation type as single-nucleotide missense
mutations (also encompassing synonymous mutations affecting
splice region, Supplementary Methods and Supplementary
Table S1) or deleterious mutations (encompassing splice site,
nonsense, in-frame, and frameshift mutations); (ii) whether the
mutations were within or outside of the DNA-binding domain.
For correlative analyses with clinicopathologic parameters, the
sample (TCGA-DD-A1EE) with three TP53 mutations (A161S,
H193R and C277∗) was classified as harboring deleterious
mutation.
The spectrum of TP53 mutations in non-LIHC TCGA
datasets were retrieved from the cbioportal (accessed June 2017,
Supplementary Table S2) (Gao et al., 2013). Mutation (lolliplot)
diagrams and Oncoprints were generated using cbioportal (Gao
et al., 2013).
Genomic and Transcriptomic Data
Analysis
Gene-level copy number (“gistic2_thresholded,” 370/373
samples) and expression (“IlluminaHiSeq,” 367/373 samples)
data were retrieved from the UCSC Xena Functional Genomics
Browser2 accessed April 2017). Gene-level copy number data
were used to define genomic regions with differential frequencies
of copy number alterations between HCCs with missense TP53
mutations, with deleterious TP53 mutations, or with wild-type
TP53. Copy number states −2, −1, 0, 1, and 2 were considered
homozygous deletion, heterozygous loss, copy number neutral,
gain and high-level gain/amplification, respectively.
Transcriptomic data were in the form of gene-level,
log-transformed, upper-quartile-normalized RSEM values.
Molecular classification was performed according to Hoshida
et al. (2009), using the Nearest Template Prediction:
http://software.broadinstitute.org/cancer/software/genepattern.
The R package limma was used to perform quantile
normalization and for differential expression analysis. Multiple
correction was performed using the Benjamini–Hochberg
method. Genes with adjusted P-value < 0.05 were considered as
differentially expressed.
The number of somatic mutations per sample was obtained




Oncogenic signature (“oncosign”) classification and the selection
of genomic features as ‘selected functional elements’ (SFEs) input
data were performed as described by Ciriello et al. (2013).
Specifically, we selected 29 significantly mutated genes that have
previously been reported as cancer genes (Futreal et al., 2004;
Fujimoto et al., 2012; Kandoth et al., 2013; Lawrence et al.,
2014), 27 recurrent amplifications and 34 recurrent deletions as
SFEs (Supplementary Methods). Robustness of the subclasses was
assessed by removing 5, 10, or 20% of samples, reclassifying the
reduced dataset, and calculating the Jaccard coefficients over 20
runs (Ciriello et al., 2013). Enrichment of genomic alterations was
assessed using Chi-squared and Fisher’s exact tests, as described
(Ciriello et al., 2013).
Mutational Signatures
Decomposition of mutational signatures was performed using
deconstructSigs (Rosenthal et al., 2016), based on the set of 30
mutational signatures (“signature.cosmic”) (Alexandrov et al.,
2013; Nik-Zainal et al., 2016), for the 358 samples with at least
30 somatic mutations. Mutational signatures with >20% weight
were considered to have substantial contribution to the overall
mutational landscape. For each sample, the mutation signature
with the highest weight was considered the dominant mutational
signature.
Pathway Analysis
Pathways analysis was performed using Ingenuity Pathway
Analysis as previously described (Piscuoglio et al., 2014;
Martelotto et al., 2015). P < 0.001 was considered significant
(Supplementary Methods).
Statistical Analysis
Associations between TP53 mutations and clinical/histologic
features were assessed using Mann–Whitney U, Chi-squared
or Fisher’s exact tests as appropriate. Survival analyses were
performed using the Kaplan-Meier method and the log-rank
test. Univariate and multivariate analyses for OS and DFS were
performed using the Cox proportional-hazards model. Mutual
exclusivity and co-occurrence of somatic mutations were defined
using the cbioportal (Gao et al., 2013). Statistical analyses
comparing copy number profiles and defining genes up-regulated
when gained or amplified and genes down-regulated when
lost were performed as previously described (Supplementary
Methods) (Piscuoglio et al., 2014). All tests were two-sided.
P < 0.05 were considered statistically significant. Statistical




Molecular Classification of HCCs
TP53 mutation status was available for 373 HCCs subjected
to whole-exome sequencing by TCGA (The Cancer Genome
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Atlas Research Network, 2017). Analysis of the clinical details
of the patients revealed that the median age at diagnosis was
61 (range 16–90) and that 67.5% were male (Supplementary
Table S3). Half of the patients were Caucasian (50.8%), with
most remaining patients being Asian (43.9%). The most frequent
primary risk factor was alcohol consumption (33.1%), followed
by HBV (30.0%) and hepatitis C virus (HCV) infection (15.9%).
Overall, history of at least one primary risk factor was noted in
74.2% patients (Supplementary Table S3).
We performed a comprehensive histopathologic review of
the diagnostic H&E slides for all 373 included cases to assess
Edmondson grade, the presence of cholestasis, Mallory bodies,
vessel infiltration, necrotic areas, and TILs (Figure 1 and
Supplementary Table S3). Most samples were of intermediate
grade, with 33.2, 60.6, and 5.4% graded as of Edmondson
grades 2, 3, and 4, respectively. No sample was classified as
of Edmondson grade 1. Cholestasis, Mallory bodies, vessel
infiltration, necrotic areas, and TILs were present in 21.6, 22.0,
34.1, 24.8, and 47.3% of cases, respectively.
Molecular classification was performed for the 367 HCCs for
which expression data were available according to Hoshida et al.
(2009). 31.3, 21.5, and 47.2% of HCCs were classified as S1, S2
and S3, respectively (Supplementary Table S3).
Spectrum of TP53 Somatic Mutations in
HCCs
Given that TP53 is one of the most frequently mutated genes in
HCCs and its diverse spectrum of mutations in human cancers,
we sought to define the spectrum and type of TP53 mutations
found in HCCs. A total of 116 somatic non-synonymous TP53
mutations and 2 synonymous TP53 mutations affecting splice
regions were identified in 115 (30.8%) cases, including one case
with three distinct mutations and one case with two. Missense
(including missense and synonymous mutations affecting splice
region, Supplementary Methods and Supplementary Table S1)
and deleterious (including nonsense, frame-shift, in-frame, splice
site) mutations accounted for 73 (62%) and 45 (38%), respectively
(Figure 2). Compared to other cancer types characterized by the
TCGA, there was no difference between HCC and non-HCC
tumor types in terms of the ratio of missense vs deleterious
mutations (P = 0.197, Fisher’s exact test).
Of the 73 missense and synonymous mutations affecting
splice region, 51 (70%) affected known hotspot residues (Chang
et al., 2016; Gao et al., 2017) and all but one (99%) affected
the DNA-binding domain (Figure 2A). All missense mutations
were predicted to be pathogenic by at least 2/5 in silico
mutation effect predictors, with the two synonymous mutations
affecting splice region also predicted to be disease causing
(Supplementary Methods and Supplementary Table S1). The
most frequent hotspot mutations were R249S (11/73, 15%),
H193R (4/73, 5%), and R248Q/W (4/73, 5%). V157F, a mutation
not considered to be a hotspot residue (Chang et al., 2016;
Gao et al., 2017) but was reported as a mutation hotspot in
HCCs (Woo et al., 2011), accounted for 4/73 (5%) of the
missense mutations (Figure 2A). Compared to other cancer
types, mutations affecting V157 and R249 accounted for greater
proportions of the missense mutations in HCCs than in other
cancer types (4/73, 5% vs. 22/1787, 1.2%, P = 0.017 and
11/73, 15% vs. 21/1787, 1.2%, P < 0.001, respectively, Fisher’s
exact tests, Figures 2A,B). In particular, R249S accounted
for <0.5% of TP53 missense mutations in non-HCC TCGA
samples, but accounted for 15% of the missense mutations
in HCCs (P < 0.001, Fisher’s exact test). In contrast, the
most frequent hotspots in non-HCC tumors R273 (178/1787,
10.0% of missense mutations) and R175 (112/1787, 6.3%)
were only observed once and not at all, respectively, in
HCCs (P = 0.008 and P = 0.020, respectively, Fisher’s exact
tests).
FIGURE 1 | Histologic features of hepatocellular carcinoma. Low-power view of hepatocellular carcinomas with tumor infiltrating lymphocytes (A), necrotic areas
(B), vessel infiltration (C), Mallory bodies (D), cholestasis (E) and of high Edmondson grade (F). Red arrows indicate the relevant histologic features.
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FIGURE 2 | The distribution and the spectrum of TP53 mutations. The distribution and spectrum of TP53 missense (A,B) and deleterious (C,D) mutations in
hepatocellular carcinoma (A,C) and in non-liver TCGA datasets (B,D). Diagrams represent the protein domains of p53 encoded by the TP53 gene. The presence of
a mutation is shown on the x axis (lollipop), and the frequency of mutations is shown on the y axis. Missense mutations are presented as green circles, deleterious
mutations (i.e., nonsense, frameshift, splice-site and in-frame) are depicted in black and brown circles. Plots were generated using cBioPortal tools
(http://www.cBioPortal.org) and curated manually.
The 45 deleterious mutations comprised 13 (29%) nonsense
point mutations, 20 (44%) frameshift small insertions or deletions
(indels), 3 (7%) in-frame indels and 9 (20%) mutations affecting
splice sites. Unlike missense mutations, the 45 deleterious
mutations were spread across the TP53 gene, with 32 (71%) in
the DNA-binding domain, 3 (7%) in the tetramerization motif
and 10 (22%) outside of these two domains (Figure 2C). In other
cancer types, recurrent truncating mutations were observed at
R196 (44/926, 4.8% of deleterious TP53 mutations) and R213
(56/926, 6.0%), both of which were not observed in HCC
(Figures 2C,D).
Our results demonstrate that the spectrum of TP53 mutations
in HCCs is distinct from that in non-HCC tumors, with
HCC-specific recurrent hotspot mutations and a near absence
of highly recurrent TP53 mutations found in other cancer
types.
TP53 Status Correlates with Specific
Histopathologic and Clinical Features of
HCCs
Next, we sought to define whether TP53 mutation status
correlated with clinicopathologic parameters. TP53 mutations
were more frequently found in male patients (35.9% vs. 20.7%
in female; P = 0.003, Fisher’s exact test) and in patients with
at least one primary risk factor (35.1% vs. 20.9%; P = 0.013,
Fisher’s exact test), especially in HCCs associated with HBV/HCV
infection (53.1% vs. 39.7%; P = 0.021, Fisher’s exact test,
Table 1). Patients from different racial backgrounds were
associated with different TP53 mutational frequencies (P= 0.001,
Chi-squared test, Table 1). Black or African Americans had
the highest frequency of TP53 mutations (70.6% vs. Asians,
36.5%, P = 0.009, and vs. Caucasians, 22.8%, P < 0.001,
Fisher’s exact tests), while Asians displayed more frequent TP53
mutations than Caucasians (P = 0.006, Fisher’s exact test). No
association with age of patients or Child-Pugh classification was
observed.
Correlation with histologic features revealed that TP53-
mutant HCCs were associated with high Edmondson grade,
accounting for 12.1, 38.5, and 65.0% of cases classified as
Edmondson grades 2, 3, and 4, respectively (P < 0.001,
Chi-squared test, Table 1). TP53 mutations were less frequent in
HCCs associated with cholestasis (17.5% vs. 38.4%; P = 0.003,
Fisher’s exact test) and were more frequent in HCCs with necrotic
areas (43.5% vs. 26.9%; P = 0.004, Fisher’s exact test, Table 1).
The presence of TILs was associated with less frequent TP53
mutations (37.4% vs. 62.6%; P = 0.013, Fisher’s exact test;
Table 1). No association was found between TP53 mutation status
and the presence of Mallory Bodies or vessel infiltration.
Further analyses comparing HCCs with missense or
deleterious mutations showed that patients with HCCs with
deleterious TP53 mutations were slightly older than those
with missense mutations (median 64 vs. 58, P = 0.049,
Mann–Whitney U test, Supplementary Table S4). After
excluding one patient (TCGA-DD-A1EE) with both deleterious
mutation (C277∗) and hotspot missense (H193R) mutations,
the ages between the two groups were not different (P = 0.058,
Mann–Whitney U test). Of note, TP53 recurrent hotspots
V157F, R158H, H193R, Y205, and R249S were exclusively
found in tumors of high Edmondson grade (grades 3/4,
P= 0.038, Fisher’s exact test, compared to HCCs with other TP53
mutations).
Correlating TP53 status with molecular classification,
(Hoshida et al., 2009) TP53-mutant HCCs were preferentially
enriched in the S1 and S2 subclasses (36.5% and 42.5% vs.
21.8% in S3, P = 0.001, Chi-squared test, Table 1). Stratifying
TP53-mutant HCCs into those with missense or deleterious
mutations did not reveal association between TP53 mutation
types and molecular classification (P = 0.459, Chi-squared test,
Supplementary Table S4).
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TABLE 1 | Analyses of TP53 status and clinicopathologic parameters in the 373 HCCs from The Cancer Genome Atlas cohort (The Cancer Genome Atlas Research
Network, 2017).
TP53 status P-value
Mutant [N (%)] Wild-type [N (%)]
Age (n = 372) Median years 59 61 0.200
Gender (n = 372) Female 25 (20.7) 96 (79.3) 0.003
Male 90 (35.9) 161 (64.1)
Child-Pugh classification grade
(n = 243)
A 65 (29.4) 156 (70.6) 0.754
B 7 (33.3) 14 (66.7)
C 0 (0) 1 (100)
Race (n = 362) America Indian or Alaskan native 1 (50) 1 (50) <0.001
Asian 58 (36.5) 101 (63.5)
Black or African American 12 (70.6) 5 (29.4)
Caucasian 42 (22.8) 142 (77.2)
History of Primary Risk Factors
(n = 353)
At least one risk factor 92 (35.1) 170 (64.9) 0.013
No risk factor 19 (20.9) 72 (79.1)
Edmondson Grade (n = 373) 2 15 (12.1) 109 (87.9) <0.001
3 87 (38.5) 139 (61.5)
4 13 (65.0) 7 (35.0)
Cholestasis (n = 370) Absent 101 (38.4) 189 (65.2) 0.003
Present 14 (17.5) 66 (82.5)
Mallory Bodies (n = 373) Absent 94 (32.3) 197 (67.7) 0.280
Present 21 (25.6) 61 (74.4)
Vessel infiltration (n = 370) Absent 72 (29.5) 172 (70.5) 0.407
Present 43 (34.1) 83 (65.9)
Necrotic areas (n = 371) Absent 75 (26.9) 204 (73.1) 0.004
Present 40 (43.5) 52 (56.5)
Infiltrating lymphocytes (n = 372) Absent 72 (62.6) 124 (48.2) 0.013
Present 43 (37.4) 133 (51.8)
Molecular classification by
Hoshida et al. (2009, n = 367)
S1 42 (36.5) 73 (63.5) 0.001
S2 31 (42.5) 42 (57.5)
S3 39 (21.8) 140 (78.2)
Statistical comparisons were performed using Mann–Whitney U test, Fisher’s exact test or Chi-Squared test. P < 0.05 was considered to be statistically significant.
These results demonstrate that, additional to the well-
established associations with the male gender, HBV/HCV
infection and high Edmondson grade, TP53 mutations were
less frequent in HCCs with cholestasis or TILs, but were more
frequent in HCCs with necrotic areas.
Genomic Instability Is Not Associated
with TP53 Mutation Type
Next, we compared the number of somatic genetic alterations
between TP53-wild-type and mutant cases. Mutational
burden was higher in TP53-mutant HCCs, HCCs with
missense TP53 mutations and HCCs with deleterious TP53
mutations than TP53-wild-type cases (P < 0.001, P < 0.001
and P = 0.004, respectively, Mann–Whitney U tests), but
no difference was observed between cases with missense
or deleterious mutations (P = 0.799, Mann–Whitney U
test, Supplementary Figure S1A). Similarly, TP53-mutant
HCCs, HCCs with missense TP53 mutations and HCCs
with deleterious TP53 mutations all harbored higher number
of genes affected by CNAs compared with TP53-wild-type
cases (P < 0.001, P < 0.001 and P = 0.001, respectively,
Mann–Whitney U tests, Supplementary Figure S1B), with no
difference between cases with missense or deleterious TP53
mutations (P = 0.352, Mann–Whitney U test, Supplementary
Figure S1B).
Consistent with their increased chromosomal instability,
TP53-mutant HCCs displayed more frequent gains of
chromosomes 1p, 3, 10p and 19p and losses of half the
genome, notably of chromosomes 4, 5, 10q, 14, 17p, 18 and 19
(Supplementary Figures S2A–C). The CNA landscapes between
HCCs with TP53 missense or deleterious mutations were
remarkably similar (Supplementary Figure S2D).
To identify potential CNA drivers associated with TP53
mutations, we interrogated the genes overexpressed when gained
and genes downregulated when lost in the regions that showed
differential CNA frequencies between TP53-mutant and TP53-
wild-type cases (Supplementary Figure S2A). Pathway analysis
of the copy number-regulated genes revealed that TP53-mutant
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FIGURE 3 | Oncogenic signature classes in TP53-mutant hepatocellular carcinoma. The pattern of mutations in TP53, CTNNB1, BAP1, RB1, JAK1 and KEAP1 in
hepatocellular carcinoma (A). Number of TP53-mutant samples classified as OSC1, OSC2, OSC3, and OSC4, according to the color key in A (B). Number of
mutational (C) and copy number (D) ‘selected functional elements’ (SFEs) in the different subclasses. The distribution of mutational vs copy number SFEs in
TP53-mutant cases (E). The shade of red is proportional to the number of samples for a given (x,y) position. Heatmap shows the mutational and copy number SFEs
altered in at least 5% of the samples in at least one oncogenic signature class (F). Shades of red and blue are proportional to the number of samples with a given
genetic alteration, according to the color key. Plot in (A) was generated using cBioPortal (http://www.cBioPortal.org) and curated manually.
cases displayed deregulation in pathways associated with EIF2
signaling, protein ubiquitination pathway, RNA polymerase-
II complex and DNA repair pathways, and in molecular and
cellular functions related to cell death and survival, cell cycle,




In HCCs, TP53 and CTNNB1 mutations were largely mutually
exclusive (P = 0.028, Figure 3A) (Fujimoto et al., 2012;
Guichard et al., 2012; Schulze et al., 2015; The Cancer Genome
Atlas Research Network, 2017). Additionally, TP53 and BAP1
mutations were also mutually exclusive (P = 0.004; Figure 3A).
In contrast, TP53 mutations co-occurred with RB1, JAK1 and
KEAP1 mutations (P = 0.028, P = 0.034 and P = 0.044,
respectively, Figure 3A). These observations suggest that TP53-
mutant HCCs likely constitute a genetically heterogeneous
subclass and may be subclassified into categories with distinct
oncogenic signatures.
To define the oncogenic signatures in TP53-mutant HCCs,
we performed unsupervised partitioning of the samples
into classes with distinct patterns of likely ‘driver’ genetic
alterations (or ‘selected functional elements,’ SFEs), (Ciriello
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et al., 2013) including mutations in 29 significantly mutated
genes, amplifications in 27 recurrently amplified regions,
and homozygous deletions in 34 recurrently deleted regions
(see Materials and Methods). Among the 144 TP53-mutant
HCCs with mutational and CNA data, we found median of
2 mutational (range 0–11) and 2.5 CNA (range 0–13) SFEs
in each case and identified four robust oncogenic signature
classes (OSCs, Figures 3B–E and Supplementary Figure S4A).
HCCs with missense or deleterious TP53 mutations did not
cluster separately (P = 0.305, Chi-squared test, Figure 3B),
nor HCCs of distinct transcriptomic subclasses (Supplementary
Figure S4B).
Inspection of the SFEs that characterized each OSC revealed
that OSC1 was defined by the presence of CTNNB1 mutations
(100%, P < 0.001, Fisher’s exact test, Figure 3F). The
most frequent alteration in OSC2 was 8q24.21 amplification
(encompassing MYC, 67%, P < 0.001, Fisher’s exact test),
while the most frequent alterations in OSC4 were 1q21.3
(encompassing CHD1L and HORMAD1, 60%) and 1q42.2
(encompassing TARBP1 and EXO1, 63%) amplifications (both
P < 0.001, Fisher’s exact tests, Figure 3F). OSC3 was notable
for lacking highly recurrent genetic alterations, with the most
frequent alteration being 11q13.3 amplification (CCND1, 23%,
P = 0.011, Fisher’s exact test). Additionally, ARID1A mutations
were enriched in OSC1 (35%, P < 0.001, Fisher’s exact test),
while 10q23.21 deletion (PTEN, 20%) and 6p25.2 amplification
(VEGFA, 23%) were enriched in OSC4 (P= 0.020 and P= 0.001,
respectively, Fisher’s exact tests). We also found that OSC1
harbored higher number of mutational SFEs and lower number
of CNA SFEs (P < 0.001 and P = 0.002, respectively, Mann–
Whitney U tests, Figures 3C,D) compared to other classes. By
contrast, OSC4 harbored higher number of CNA SFEs than
the other classes (P < 0.001, respectively, Mann–Whitney U
test, Figure 3D). The TP53 R249S hotspot mutation was not
associated with specific OSC classes (P = 0.591, Chi-squared
test). Finally, OSC1/2 were more frequently associated with the
presence of TILs than OSC3/4 (P = 0.028, Chi-squared test).
No other associations between histologic or clinicopathologic
parameters and OSCs were found.
These observations are concordant with the observation
that tumors are primarily driven by either somatic mutations
or CNAs but rarely both (Ciriello et al., 2013) (Figure 3E
and Supplementary Figures S4C,D). Furthermore, we identified
subclasses of TP53-mutant HCCs likely driven by co-occurring
CTNNB1 mutations, 8q24.21 (MYC) amplification or 1q
amplification in a mutually exclusive manner.
Mutational Signatures in TP53-Mutant
HCCs
The somatic mutational landscapes are shaped by endogenous
and/or environmental biological and chemical processes
(Alexandrov et al., 2013). More than 10 mutational signatures
have been identified in liver cancers, including two liver cancer-
specific signatures 12 and 16 of unknown etiology, both of
which are characterized by frequent T>C substitutions but
with different sequence contexts (Alexandrov et al., 2013).
To determine whether TP53-mutant HCCs harbored distinct
mutational signatures compared to TP53-wild-type HCCs,
we inferred the underlying mutational processes for the 358
HCCs with at least 30 somatic mutations (Alexandrov et al.,
2013; Nik-Zainal et al., 2016). The age-associated signature 5,
(Alexandrov et al., 2015) and the liver cancer-specific signatures
12 and 16 contributed substantially (≥20% weight) to the
mutational landscapes in 17.0, 12.8, and 53.4% of the samples,
respectively (Figure 4). Together, 72.9% of HCCs harbored
signatures 5, 12 or 16 as the dominant signatures (14.0, 10.6, and
48.3%, respectively).
A comparison of the mutational signatures with substantial
contribution (≥20%) to the mutational landscapes of TP53-
mutant or TP53-wild-type HCCs revealed that only the aflatoxin-
associated signature 24 was enriched among TP53-mutant HCCs
(7/114, 6.1% vs. 4/244, 1.6%, P= 0.042, Fisher’s exact test).
We further compared the mutational signatures between
HCCs with missense or deleterious TP53 mutations.
Interestingly, while 18.6% (13/70) of samples with missense
TP53 mutations displayed substantial contribution from
signature 12, only 4.5% (2/44) of samples harboring deleterious
TP53 mutations did (P = 0.044, Fisher’s exact test), with
signature 12 being the dominant signature in 15.7% (11/70)
and 2.3% (1/44) of samples with missense or deleterious TP53
mutations, respectively (P = 0.027, Fisher’s exact test, Figure 4).
No difference in other signatures was observed. The aflatoxin-
associated signature 24 was enriched among R249S-mutant
HCCs compared other TP53-mutant HCCs (4/11, 36% vs. 3/103,
3%, P = 0.001 for substantial contribution and 3/11, 27% vs.
2/103, 2%, P= 0.006 for dominant signature, Fisher’s exact tests).
Taken together, our results suggest that the different types
of TP53 mutations were associated with distinct mutational
processes. Specifically, signature 12 was rarely found in HCCs
with deleterious TP53 mutations.
Distinct Types of TP53 Mutations Are
Associated with Different Prognoses
Previous studies found that associations between the types of
TP53 mutations and prognoses in breast, and head and neck
cancers (Olivier et al., 2006; Ozcelik et al., 2007; Vegran et al.,
2013; Lapke et al., 2016). Here we hypothesized that patients
with HCCs harboring TP53 missense or deleterious mutations
may display different prognoses. Considering the patients with
available data on OS (n = 372) or DFS (n = 321), we found that
patients with TP53-mutant HCCs displayed a more aggressive
behavior including shorter OS and DFS than TP53-wild-type
patients (P = 0.018 and P = 0.005, respectively, log-rank tests,
Figure 5). Patients with missense or deleterious TP53 mutations
did not differ in OS or DFS (P = 0.129 and P = 0.148,
respectively, log-rank tests, Figure 5). Importantly, while patients
with deleterious TP53 mutations had worse OS and DFS than
TP53-wild-type patients (P = 0.004 and P = 0.001, respectively,
log-rank tests, Figure 5), there was no difference in OS or DFS
between patients with missense TP53 mutations and those wild-
type for TP53 (P = 0.192 and P = 0.084, respectively, log-rank
tests, Figure 5).
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FIGURE 4 | Mutational signatures in hepatocellular carcinoma with and without TP53 somatic mutations. Heatmap depicting the mutational signatures that shaped
the genomes of the tumor samples analyzed (A) (Alexandrov et al., 2013). The similarity of the pattern of substitutions to the published mutational signatures is
indicated in blue according to the color key. HCC samples were divided according to their TP53 mutational status. Mutational signatures were sorted by the number
of cases classified as having a given mutational signature as the dominant signature, in decreasing order. Barplots illustrating examples of mutational signatures 12
(upper) and 24 (bottom) (B). In each panel, the colored barplot illustrates each mutational signature according to the 96 substitution classification defined by the
substitution classes (C>A, C>G, C>T, T>A, T>C, and T>G bins) and the 5′ and 3′ sequence context, normalized using the observed trinucleotide frequency in the
human exome to that in the human genome. The bars are ordered first by mutation classes (C>A/G>T, C>G/G>C, C>T/G>A, T>A/A>T, T>C/A>G, T>G/A>C),
then by the 5′ flanking base (A, C, G, T) and then by the 3′ flanking base (A, C, G, T).
As an exploratory analysis, we asked whether OSCs or
mutational signatures of TP53-mutant HCCs were prognostic.
Compared to OSC1 (28 months), OSC2 (26 months) and
OSC3 (median not reached), OSC4 was associated with the
shortest median OS of 14 months, although the difference
was not statistically significant (P = 0.366, log-rank test;
Supplementary Figure S4E). Univariate Cox regression
analyses revealed that the aflatoxin-associated signature 24
(HR 3.275, CI 1.279–8.384, P = 0.013), HBV infection status
and the presence of necrotic areas were associated with
poor prognosis (Supplementary Table S5). However, in a
multivariate analysis, mutational signature 24 was not an
independent prognostic indicator (P = 0.242; Supplementary
Table S5).
Taken together, our results showed only patients with
deleterious TP53 mutations but not missense TP53 mutations
were associated with significantly worse OS and DFS in this
cohort.
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FIGURE 5 | TP53 mutation status is associated with worse overall and disease-free survival. Overall (A) and disease-free survival (B) of HCC patients with and
without TP53 somatic mutations using the Kaplan–Meier method. Median survival for each group is indicated in parentheses. Statistical comparisons were
performed using log-rank tests. P < 0.05 was considered statistically significant.
DISCUSSION
In this study, we performed a detailed analysis of TP53
somatic mutational spectrum in HCCs, with nearly all missense
mutations (98%) and most deleterious mutations (73%) affecting
the DNA-binding domain. Notably, we found that the residues
mutated in HCCs differed from those in other cancer types.
Hotspot mutations R249S and V157F were common in
HCCs but extremely rare in other cancers, while mutations
affecting R175 and R273, two of the most frequently mutated
residues in other cancers, were nearly absent in HCCs. This
latter observation also applies to other HCC datasets (Ahn
et al., 2014; Schulze et al., 2015), suggesting that TP53
mutational spectrum in HCC is distinct from that in other
cancers.
To determine the genotype–phenotype correlation between
TP53 mutation status and clinicopathologic parameters, we
performed a detailed assessment of histologic features using
H&E slides. We confirmed the established associations with the
male gender, HBV/HCV infection and high Edmondson grade.
Additionally, TP53 mutations were associated with the presence
of necrotic areas, and accordingly, with the absence of cholestasis,
a feature more frequently observed in well-differentiated HCCs.
Finally, we observed that the presence of TILs was associated
with less frequent TP53 mutations, in line with the favorable
prognosis associated with tumors with high TILs in other tumor
types (Mahmoud et al., 2011).
Analysis of the mutational signatures revealed that signatures
16 of unknown etiology and the age-associated signature 5
(Alexandrov et al., 2015) were the most prevalent in HCCs. We
also found that signature 12 of unknown etiology, characterized
by frequent T>C substitutions, was prevalent in TP53-wild-
type and HCCs with missense TP53 mutations but were largely
absent in those with deleterious TP53 mutation. A previous
study reported that the W3 signature, which was highly similar
to signature 12 (Fujimoto et al., 2012), was associated with
the age of patients. Here we found no difference in the age
of patients when we considered tumors with strictly missense
or deleterious TP53 mutations (i.e., excluding one patient
with both types). The basis of signature 12 is thus unclear
and further studies are required to elucidate its biological
significance.
Adopting the algorithm of “oncosign” (Ciriello et al., 2013),
we identified four robust subclasses of TP53-mutant HCCs with
distinct oncogenic signatures. Of these classes, one subclass was
likely driven by co-occurring CTNNB1 mutations, while two
subclasses were likely driven by amplicon drivers on 1q and
8q. 1q21 amplification has been linked to hepatocarcinogenesis,
with ALC1 (CHD1L) overexpression in HCC cells shown to
promote G1/S phase transition and to inhibit apoptosis (Ma
et al., 2008). The authors further suggested that the oncogenic
function of ALC1 might be associated with its role in promoting
cell proliferation by down-regulating p53 expression (Ma et al.,
2008). The 1q21 amplicon also contains HORMAD1, a gene
that has been shown to drive chromosomal instability in breast
cancer (Watkins et al., 2015). As for 8q24, in addition to the
well-known oncogenic role of MYC, previous studies have also
shown that MYC amplification is an indicator of malignant
potential and poor prognosis in HCC (Lin et al., 2010), and
that the co-occurrence of MYC amplification and p53 alteration
may contribute to HCC progression (Kawate et al., 1999).
The remaining subclass did not have highly recurrent genetic
alterations. Interestingly, this subclass was numerically, though
not statistically, associated with the most favorable OS among the
four classes. One may speculate that TP53-mutant HCCs lacking
additional drivers may constitute a less aggressive subclass.
Of note, the features that characterized the four OSCs were
largely mutually exclusive, suggesting that distinct oncogenic
processes are operative in non-overlapping subsets of TP53-
mutant HCCs.
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TP53 mutation status predicts worse OS and DFS in HCC
patients (Yano et al., 2007; Woo et al., 2011; Cleary et al., 2013).
However, we found that patients with deleterious mutations, but
not those with missense mutations, were associated with worse
OS and DFS compared to patients wild-type for TP53. This
is in line with other tumor types, in which different types of
TP53 mutations have been associated with different prognoses
(Olivier et al., 2006; Ozcelik et al., 2007; Vegran et al., 2013;
Lapke et al., 2016). In fact, the risk of death or relapse for
patients harboring deleterious mutation is 2.3 times (HR = 2.36
and 2.063, respectively) higher than TP53-wild-type patients.
The prognosis for patients with missense mutations appears
to sit between those with wild-type TP53 or deleterious TP53
mutations, albeit not statistically different from either group. It is
conceivable that the prognostic significance of the type of TP53
mutations may be confirmed in a larger cohort with extensive
follow-up.
It has been suggested that TP53 missense mutations have
varying capacity to transactivate p53 target genes and to
alter the responsiveness to chemotherapeutic agents in breast
cancer (Jordan et al., 2010). A differential expression analysis
using the HCC TCGA dataset comparing HCCs with TP53
missense mutations and those with TP53 deleterious mutations
identified TP53 itself as up-regulated but did not identify
significantly altered genes (data not shown). Furthermore,
HCCs harboring the missense mutations functionally shown
to lack the ability to transactivate genes with p53 response
elements (Jordan et al., 2010) did not differ from HCCs with
other missense mutations on the transcriptomic level (data
not shown). It is thus unclear precisely how the various TP53
mutations may differentially alter the transcriptomic landscape
of HCCs. Further functional studies may be required to elucidate
how the types of TP53 mutations may affect its biological
functions.
In HCC molecular characterization studies to date, HCCs are
typically classified as TP53-wild-type or TP53-mutant, where all
TP53 mutations were treated as equal (Fujimoto et al., 2012;
The Cancer Genome Atlas Research Network, 2017). However,
many studies have demonstrated that TP53 can be affected by
either (or both) gain-of-function or loss-of-function mutations,
with missense mutations preferentially displaying gain-of-
function or neomorphic properties (Muller and Vousden, 2014).
Our study has demonstrated that HCCs with missense or
deleterious TP53 mutations display similar clinicopathologic
features, mutational/CNA burden and oncogenic signatures, but
are associated with distinct mutational signatures. Clinically,
while patients with tumors harboring deleterious TP53 mutations
had worse prognosis compared to those wild-type for TP53,
there was no statistically significant difference between those with
missense mutations and those wild-type for TP53. Our study
highlights the importance to consider the type of TP53 mutations
in studies of biomarkers and molecular characterization of
HCCs.
Our study has limitations. Despite TCGA being the largest
genomic study of HCC, it is by no means the only large-
scale study. However, as one of our aims was to define
clinicopathologic correlates, we chose TCGA as it is the only
study with publicly available H&E slides for pathology review.
Secondly, the power of the OS and DFS analyses was limited due
to the cohort size. Further studies may reveal whether prognosis
is related to the type of TP53 mutations, as has been shown in
other cancers. Thirdly, our analyses did not consider the non-
coding genome due to the nature of the sequencing performed
by the TCGA. Given the frequent mutations in non-coding
regions such as TERT promoter, MALAT1 and NEAT1 (Fujimoto
et al., 2012; Schulze et al., 2015), it is conceivable that additional
oncogenic signatures within TP53-mutant HCCs may emerge.
CONCLUSION
Our study highlights the genetic heterogeneity among TP53-
mutant HCCs and that patients with HCCs harboring different
types of TP53 mutations may be associated with distinct
prognoses. Future work will be required to elucidate whether
the co-occurring genetic alterations act synergistically with TP53
mutations to promote carcinogenesis in HCCs.
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